Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Christopher J. Walker"'
Autor:
Jessica Kohlschmidt, Richard Stone, Dimitrios Papaioannou, Clara D. Bloomfield, Adrienne M. Dorrance, Marius Bill, Bayard L. Powell, Andrew J. Carroll, Deedra Nicolet, Jonathan E. Kolitz, Ramiro Garzon, John C. Byrd, Ann-Kathrin Eisfeld, Zachary Brannan, Xiaoqing Rong-Mullins, Krzysztof Mrózek, Kellie J. Archer, Christopher J. Walker
Publikováno v:
Haematologica
Leukemia stem cells (LSC) are more resistant to standard chemotherapy and their persistence during remission can cause relapse, which is still one of the major clinical challenges in the treatment of acute myeloid leukemia (AML). A better understandi
Autor:
Adrienne M. Dorrance, Aparna Pathmanathan, Jessica Kohlschmidt, Xiaoli Zhang, Marius Bill, Allison LaRocco, Zachary Brannan, Dimitrios Papaioannou, Clara D. Bloomfield, Krzysztof Mrózek, Stefano Volinia, Ramiro Garzon, Christopher J. Walker, Felice Pepe, Allison E. Walker, Malith Karunasiri
Publikováno v:
Leukemia. 33:2169-2182
In acute myeloid leukemia (AML), novel therapies are needed to target not only the rapidly dividing AML blasts but also the distinct population of leukemia stem cells (LSCs), which have abnormal self-renewal capacity and increased chemotherapy resist
Autor:
Lorenzo Stramucci, Christopher J. Walker, Paolo Vigneri, Catriona Jamieson, Ann-Kathrin Eisfeld, Francesco Dazzi, Peter Hokland, Danilo Perrotti, Katerina Machova Polakova, Maria R. Baer, Giovannino Silvestri, Christopher Harman, Jason G. Harb, Jane F. Apperley, Dragana Milojkovic, Justin Ellis, Ramiro Garzon, Ying Zou, Bin Zhang, Jianfei Qi, Xiaoxuan Fan, Moutuaata M. Moutuou, Philippa C. May, Martin Guimond, Georgios Nteliopoulos, Carlo Gambacorti-Passerini, Alistair Reid, Paolo Neviani, Shuzhen Wang, Klara Srutova, Denis-Claude Roy, Garrett Fitzgerald, Guido Marcucci, Michael W. Deininger, Gabriel Pineda, Fabio Stagno, Rossana Trotta, Bruno Calabretta
Publikováno v:
Silvestri, G, Trotta, R, Stramucci, L, Ellis, J J, Harb, J G, Neviani, P, Wang, S, Eisfeld, A-K, Walker, C J, Zhang, B, Srutova, K, Gambacorti-Passerini, C, Pineda, G, Jamieson, C H M, Stagno, F, Vigneri, P, Nteliopoulos, G, May, P C, Reid, A G, Garzon, R, Roy, D-C, Moutuou, M M, Guimond, M, Hokland, P, Deininger, M W, Fitzgerald, G, Harman, C, Dazzi, F, Milojkovic, D, Apperley, J F, Marcucci, G, Qi, J, Polakova, K M, Zou, Y, Fan, X, Baer, M R, Calabretta, B & Perrotti, D 2020, ' Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on MIR300 Antiproliferative and PP2A-Activating Functions ', Blood cancer discovery, vol. 1, no. 1, pp. 48-67 . https://doi.org/10.1158/0008-5472.BCD-19-0039
Persistence of drug-resistant quiescent leukemic stem cells (LSC) and impaired natural killer (NK) cell immune response account for relapse of chronic myelogenous leukemia (CML). Inactivation of protein phosphatase 2A (PP2A) is essential for CML-quie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27ba87a540a1e3db205ecd412f273cf0
https://hdl.handle.net/20.500.11769/548855
https://hdl.handle.net/20.500.11769/548855
Autor:
Connor A. Emdin, Mark J. Daly, Aki S. Havulinna, Aitzkoa Lopez de Lapuente Portilla, Saiju Pyarajan, Christopher P. Nelson, Pradeep Natarajan, Bo Li, Tuomo Kiiskinen, Benjamin M. Neale, Aviv Regev, John E. Dick, Christopher J. Walker, Marcin Tabaka, Xiaotian Liao, Juha Karjalainen, Aarno Palotie, Claire Churchhouse, Christopher J. O'Donnell, Daryl E. Klein, Peter W.F. Wilson, Michael Milyavsky, Vijay G. Sankaran, Albert de la Chapelle, Olga I. Gan, Caleb A. Lareau, Alexander G. Bick, Björn Nilsson, Erik L. Bao, Nilesh J. Samani, Satish K. Nandakumar, Veryan Codd, J. Michael Gaziano, Sekar Kathiresan, Kelly Cho
Publikováno v:
Nature
Myeloproliferative neoplasms (MPNs) are blood cancers that are characterized by the excessive production of mature myeloid cells and arise from the acquisition of somatic driver mutations in haematopoietic stem cells (HSCs). Epidemiological studies i
Autor:
Jacek Bielawski, Adrienne M. Dorrance, William Blum, Jason G. Harb, Rebecca B. Klisovic, Alistair Reid, Paolo Neviani, Stefano Volinia, Dragana Milojkovic, Carolyn Paisie, Mark Wunderlich, Ramasamy Santhanam, Denis-Claude Roy, Steffen Koschmieder, James C. Mulloy, Sahar A. Saddoughi, Ching-Shih Chen, Tessa L. Holyoake, Anna M. Eiring, Yihui Ma, Peter Hokland, Joshua J. Oaks, Jorge E. Cortes, Carlo M. Croce, Claudia S. Huettner, Steven M. Devine, Christopher J. Walker, Janelle A. Solt, Jane F. Apperley, Michael A. Caligiuri, Guido Marcucci, Hsiaoyin C. Mao, Justin Ellis, Ralph B. Arlinghaus, John M. Goldman, Bin Zhang, Ramiro Garzon, Ravi Bhatia, Chaode Sun, Gregory Ferenchak, Besim Ogretmen, Robert Bittman, Danilo Perrotti, John C. Byrd, Philippa C. May
Publikováno v:
Neviani, P, Harb, J G, Oaks, J J, Santhanam, R, Walker, C J, Ellis, J J, Ferenchak, G, Dorrance, A M, Paisie, C A, Eiring, A M, Ma, Y, Mao, H C, Zhang, B, Wunderlich, M, May, P C, Sun, C, Saddoughi, S A, Bielawski, J, Blum, W, Klisovic, R B, Solt, J A, Byrd, J C, Volinia, S, Cortes, J, Huettner, C S, Koschmieder, S, Holyoake, T L, Devine, S, Caligiuri, M A, Croce, C M, Garzon, R, Ogretmen, B, Arlinghaus, R B, Chen, C-S, Bittman, R, Hokland, P, Roy, D-C, Milojkovic, D, Apperley, J, Goldman, J M, Reid, A, Mulloy, J C, Bhatia, R, Marcucci, G & Perrotti, D 2013, ' PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells ', Journal of Clinical Investigation, vol. 123, no. 10, pp. 4144-57 . https://doi.org/10.1172/JCI68951
The success of tyrosine kinase inhibitors (TKIs) in treating chronic myeloid leukemia (CML) depends on the requirement for BCR-ABL1 kinase activity in CML progenitors. However, CML quiescent HSCs are TKI resistant and represent a BCR-ABL1 kinase–in
Autor:
Jonathan E. Kolitz, Jessica Kohlschmidt, Christopher J. Walker, A-K Eisfeld, Richard Stone, Maria R. Baer, Shelley Orwick, James S. Blachly, John C. Byrd, A de la Chapelle, Deedra Nicolet, Clara D. Bloomfield, Maryam Bainazar, Karl Kroll, Andrew J. Carroll, Chandni Shah, Sebastian Schwind, Bayard L. Powell, Krzysztof Mrózek
Publikováno v:
Leukemia. 31(6)
Core-binding factor acute myeloid leukemia (CBF-AML) is defined by the presence of either t(8;21)(q22;q22)/RUNX1-RUNX1T1 or inv(16)(p13.1q22)/t(16;16)(p13.1;q22)/CBFB-MYH11. The resulting fusion genes require a “second hit” to initiate leukemogen
Autor:
Christopher J. Walker, Denis-Claude Roy, B J Chyla, G. Marcucci, Joshua J. Oaks, Jason G. Harb, Paolo Neviani, Peter Hokland, Justin Ellis, Michael A. Caligiuri, Claudia S. Huettner, Gregory Ferenchak, Danilo Perrotti
Publikováno v:
Harb, J G, Neviani, P, Chyla, B J, Ellis, J J, Ferenchak, G J, Oaks, J J, Walker, C J, Hokland, P, Roy, D, Caligiuri, M A, Marcucci, G, Huettner, C S & Perrotti, D 2013, ' Bcl-xL anti-apoptotic network is dispensable for development and maintenance of CML but is required for disease progression where it represents a new therapeutic target ', Leukemia, vol. 27, no. 10, pp. 1996-2005 . https://doi.org/10.1038/leu.2013.151
The dismal outcome of blast crisis chronic myelogenous leukemia (CML-BC) patients underscores the need for a better understanding of the mechanisms responsible for the development of drug resistance. Altered expression of the anti-apoptoticBcl-xL has
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9010501d516f048c6353c6e29f4345a8
https://pure.au.dk/portal/da/publications/bclxl-antiapoptotic-network-is-dispensable-for-development-and-maintenance-of-cml-but-is-required-for-disease-progression-where-it-represents-a-new-therapeutic-target(a3d9e9d9-3948-494f-9efa-746d18dd6ade).html
https://pure.au.dk/portal/da/publications/bclxl-antiapoptotic-network-is-dispensable-for-development-and-maintenance-of-cml-but-is-required-for-disease-progression-where-it-represents-a-new-therapeutic-target(a3d9e9d9-3948-494f-9efa-746d18dd6ade).html
Autor:
Jason G. Harb, Yosef Landesman, Danilo Perrotti, Gregory Ferenchak, Christopher J. Walker, Sharon Shacham, Justin Ellis, Paolo Neviani, Ramasamy Santhanam, Joshua J. Oaks, Guido Marcucci, Michael Kauffman
Publikováno v:
Blood. 120:35-35
Abstract 35 As tyrosine kinase inhibitors (TKIs) do not induce long-term response in blast crisis chronic myeloid leukemia (CML-BC) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), and are unable to kill quiescent Ph+ hemat
Autor:
Michael Kauffman, Ramasamy Santhanam, Joshua J. Oaks, Paolo Neviani, Guido Marcucci, Jason G. Harb, Sharon Shacham, Christopher J. Walker, Carolyn Paisie, Danilo Perrotti
Publikováno v:
Blood. 118:3758-3758
Abstract 3758 Despite the remarkable response in chronic phase CML, tyrosine kinase inhibitor (TKI)-based therapies do not induce long-term response in myeloid or lymphoid blast crisis CML (CML-BC) and Ph+ ALL, and are unable to kill quiescent Ph+ he
Autor:
Robert Bittman, Tessa L. Holyoake, Danilo Perrotti, Joshua J. Oaks, Ravi Bhatia, Peter Hokland, Charlene Mao, Ramasamy Santhanam, Guido Marcucci, Michael A. Caligiuri, Bin Zhang, Carolyn Paisie, Anna M. Eiring, Christopher J. Walker, Ralph B. Arlinghaus, Denis-Claude Roy, Ching-Shih Chen, Jason G. Harb, Jorge E. Cortes, Yihui Ma, Paolo Neviani, Stefano Volinia, Bastianella Perazzona, Claudia S. Huettner
Publikováno v:
Cancer Research. 71:LB-109
Background: The success of tyrosine kinase inhibitors (TKIs) depends on the addiction of Philadelphia-positive (Ph+) CML progenitors to BCR-ABL1 kinase activity. However, CML quiescent hematopoietic stem cells (HSC) are TKI-resistant and represent an